Samsung Bioepis Co., Ltd. today announced that the European Commission (EC) has granted marketing authorization for OBODENCE™ (60mg pre-filled syringe ...

Samsung Bioepis Co., Ltd. today announced that the European Commission (EC) has granted marketing authorization for OBODENCEtm (60mg pre-filled syringe) and XBRYKtm (120mg vial), denosumab biosimilars ...

Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for OSPOMYV™ (denosumab-dssb; SB16; 60 mg pre-filled ...

One of the largest healthcare companies in India, Abbott sells a wide range of products, including medicines, nutrition, ...

Biologic medicines have transformed treatment for numerous chronic and life-threatening conditions such as cancer, ...

Market OverviewThe Global Breast Cancer Therapeutics Market  remains one of the most prevalent forms of cancer worldwide, ...

We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...

The Department of Veterans Affairs (VA) saved $67 million in 2023 through its strong adoption of biosimilars to curb the high ...

Market OverviewThe Global Generic Drugs Market was valued at $411.99 Billion in 2022 and is projected to reach $613.34 ...